Chain Pharmacy

Latest News


CME Content


Too much manpower?

The days of too many jobs chasing too few pharmacists are history. Today the situation is reversed. Is the situation grim for new pharmacists seeking to enter the market? Not necessarily, says one expert.

Letters June 2011

Readers speak out about pill-splitting, depression screening, the POWER program, rapping pharmacists, and more

New Products

A survey of new Rx, new generic, and new OTC products

An accurate understanding of the effectiveness of medications, which guides decisions about their optimal use, depends on a critical appraisal of published literature, according to Alvin Goo, PharmD. Goo is a clinical pharmacist with Harborview Medical Center and clinical associate professor, University of Washington School of Pharmacy and Family Medicine, Seattle.

The results are in, and this year Health Mart wins by a landslide. Pharmacy owner Timothy Davis and other satisfied franchisees tell us why.

A meta-analysis of studies on recurrent venous thromboembolism; updated guidelines for management of atrial fibrillation; a meta-analysis of studies comparing generic and branded warfarin

Only 5 years ago, all they heard was "pharmacist shortage, great jobs, great benefits, great pay." Now the opportunities pharmacy students dreamed about when they began school in 2007 are no longer available.

A new continuing education reporting system sponsored by NABP and ACPE should be in use by the end of the year. In order to receive credit for CPE activities, applicants will provide their NABP e-Profile ID and date of birth. IDs may be obtained at the NABP website.

After the earthquake

A young pharmacist recounts his experience of volunteering in Haiti after the earthquake.

Pharmacists are often reluctant to apologize. One fear is that lawyers may use their statements against them. Another fear is that they may be violating their own malpractice insurance policies. But there can be advantages to saying, "I made a mistake; I am sorry." A patient may be saved and a possibly explosive situation may be cooled. For most of us, it is the natural thing to do.

FDA has approved azilsartan medoxomil 40-mg and 80-mg tablets for the treatment of hypertension, either alone or in combination with other antihypertensive agents. FDA has also approved roflumilast as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations (not the relief of acute bronchospasm).

Frustrated by its lack of success at reining in drug-company abuses, FDA is bringing back a legal doctrine spawned by long-dead rodents to bring criminal charges against pharmaceutical executives, including executives who had no personal knowledge of company misdeeds.

Pharmacists need to leverage any tool that will minimize the demands placed on them and reduce distractions that can lead to medication errors, longer patient waiting time, and other complications. One available tool is the call center.